Advances in the psychopharmacotherapy of bipolar disorder type I

References

• Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol. 2007;3(1):137–158.
   PubMedGoogle Scholar
• Ketter TA. Nosology, diagnostic challenges, and unmet needs in managing bipolar disorder. J Clin Psychiatry. 2010 Oct;71(10):e27.
   PubMedGoogle Scholar
• Stewart C, El-Mallakh RS. Is bipolar disorder overdiagnosed among patients with substance abuse? Bipolar Disord. 2007 Sep;9(6):646–648.
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Garno JL, Callahan AM, et al. Overdiagnosis of bipolar disorder among substance use disorder in patients with mood instability. J Clin Psychiatry. 2008 Nov;69(11):1751–1757.
   PubMedGoogle Scholar
• Zimmerman M, Ruggero CJ, Chelminski I, et al. Is bipolar disorder overdiagnosed? J Clin Psychiatry. 2008 Jun;69(6):935–940.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003 Jan;64(1):53–59.
   PubMed Web of Science ®Google Scholar
• Albanese MJ, Clodfelter RC Jr, Pardo TB, et al. Underdiagnosis of bipolar disorder in men with substance use disorder. J Psychiatr Pract. 2006 Mar;12(2):124–127. .
   PubMedGoogle Scholar
• Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med. 1997 Sep;27(5):1079–1089.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Stang P, Wittchen HU, et al. Lifetime co-morbidities between social phobia and mood disorders in the US national comorbidity survey. Psychol Med. 1999 May;29(3):555–567.
   PubMed Web of Science ®Google Scholar
• McMillan GP, Timken DS, Lapidus J, et al. Underdiagnosis of comorbid mental illness in repeat DUI offenders mandated to treatment. J Subst Abuse Treat. 2008 Apr;34(3):320–325.
   PubMed Web of Science ®Google Scholar
• Salloum IM, Brown ES. Management of comorbid bipolar disorder and substance use disorders. Am J Drug Alcohol Abuse. 2017 Jul;43(4):366–376.
   PubMed Web of Science ®Google Scholar
• Barbato N, Hafner RJ. Comorbidity of bipolar and personality disorder. Aust N Z J Psychiatry. 1998 Apr;32(2):276–280.
   PubMed Web of Science ®Google Scholar
• Bezerra-Filho S, Galvão-de Almeida A, Studart P, et al. Personality disorders in euthymic bipolar patients: a systematic review. Braz J Psychiatry. 2015 Apr-Jun;37(2):162–167.
   PubMedGoogle Scholar
• Weinstock LM, Gaudiano BA, Epstein-Lubow G, et al. Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission. Psychiatry Res. 2014;216(1):24–30.
   PubMed Web of Science ®Google Scholar
• Rhee TG, Olfson M, Nierenberg AA, et al. 20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry. 2020 Aug 1;177(8):706–715.
   PubMed Web of Science ®Google Scholar
• He H, Hu C, Ren Z, et al. Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: results from the global burden of disease study 2017. J Psychiatr Res. 2020 Jun;125:96–105.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The international society for bipolar disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013 Nov;170(11):1249–1262.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and International society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97–170.
   PubMed Web of Science ®Google Scholar
• Divac N, Marić NP, Damjanović A, et al. Use or underuse of therapeutic guidelines in psychiatry? Psychiatr Danub. 2009 Jun;21(2):224–229.
   PubMed Web of Science ®Google Scholar
• Shafti SS. Aripiprazole versus lithium in management of acute mania: a randomized clinical trial. East Asian Arch Psychiatry. 2018 Sep;28(3):80–84.
   PubMedGoogle Scholar
• Mahajan V, Arora M, Tandon VR, et al. Efficacy and safety of asenapine versus olanzapine in combination with divalproex for acute mania: a randomized controlled trial. J Clin Psychopharmacol. 2019 Jul /Aug;39(4):305–311.
   PubMed Web of Science ®Google Scholar
• Findling RL, Earley W, Suppes T, et al. Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. Neuropsychiatr Dis Treat. 2018 Aug;2(14):1941–1952.
   Google Scholar
• Ketter TA, Durgam S, Landbloom R, et al. Long-term safety and tolerability of asenapine: a double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder. J Affect Disord. 2017 Jan ;1(207):384–392.
   Google Scholar
• Citrome L, Landbloom R, Chang CT, et al. Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. Neuropsychiatr Dis Treat. 2017 Dec;11(13):2955–2963.
   Google Scholar
• Landbloom RL, Mackle M, Wu X, et al. Asenapine: efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. J Affect Disord. 2016 Jan 15;190:103–110.
   PubMed Web of Science ®Google Scholar
• Findling RL, Landbloom RL, Mackle M, et al. Long-term safety of asenapine in pediatric patients diagnosed with bipolar I disorder: a 50-week open-label, flexible-dose trial. Paediatr Drugs. 2016 Oct;18(5):367–378.
   PubMed Web of Science ®Google Scholar
• Findling RL, Landbloom RL, Szegedi A, et al. Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. J Am Acad Child Adolesc Psychiatry. 2015 Dec;54(12):1032–1041.
   PubMed Web of Science ®Google Scholar
• Earley W, Durgam S, Lu K, et al. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord. 2018 Jan ;15(226):239–244.
   Google Scholar
• Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015 Feb;17(1):63–75.
   PubMed Web of Science ®Google Scholar
• Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015 Mar;15(174):296–302.
   Google Scholar
• Calabrese JR, Keck, Jr PE Jr., Starace A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015 Mar;76(3):284–292.
   PubMed Web of Science ®Google Scholar
• Vieta E, Durgam S, Lu K, et al. Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II/III trials. Eur Neuropsychopharmacol. 2015 Nov;25(11):1882–1891.
   PubMed Web of Science ®Google Scholar
• Arabzadeh S, Ameli N, Zeinoddini A, et al. Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disord. 2015 Sep;17(6):606–614.
   PubMed Web of Science ®Google Scholar
• Grunze H, Kotlik E, Costa R, et al. Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. J Affect Disord. 2015 Mar;15(174):70–82.
   Google Scholar
• San L, Estrada G, Oudovenko N, et al. PLACID study: a randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. Eur Neuropsychopharmacol. 2018 Jun;28(6):710–718.
   PubMed Web of Science ®Google Scholar
• Dandash O, Yucel M, Daglas R, et al. Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania. Transl Psychiatry. 2018 Mar 6;8(1):59.
   PubMedGoogle Scholar
• Berk M, Dandash O, Daglas R, et al. Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. Transl Psychiatry. 2017 Jan 24;7(1):e1011.
   PubMedGoogle Scholar
• Young RC, Mulsant BH, Sajatovic M, et al. GERI-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry. 2017 Nov 1;174(11):1086–1093.
   PubMed Web of Science ®Google Scholar
• Landersdorfer CB, Findling RL, Frazier JA, et al. Lithium in paediatric patients with bipolar disorder: implications for selection of dosage regimens via population pharmacokinetics/pharmacodynamics. Clin Pharmacokinet. 2017 Jan;56(1):77–90.
   PubMed Web of Science ®Google Scholar
• Habibi N, Dodangi N, Nazeri A. Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial. Med J Islam Repub Iran. 2017 Mar;1(31):16.
   Google Scholar
• Strakowski SM, Fleck DE, Welge J, et al. fMRI brain activation changes following treatment of a first bipolar manic episode. Bipolar Disord. 2016 Sep;18(6):490–501.
   PubMed Web of Science ®Google Scholar
• Bauer MS, Miller CJ, Li M, et al. A population-based study of the comparative effectiveness of second-generation antipsychotics vs older antimanic agents in bipolar disorder. Bipolar Disord. 2016 Sep;18(6):481–489.
   PubMed Web of Science ®Google Scholar
• Findling RL, Robb A, McNamara NK, et al. Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. Pediatrics. 2015 Nov;136(5):885–894.
   PubMed Web of Science ®Google Scholar
• Quested DJ, Gibson JC, Sharpley AL, et al. Melatonin in acute mania investigation (MIAMI-UK). A randomized controlled trial of add-on melatonin in bipolar disorder. Bipolar Disord. 2020 May 31. doi: 10.1111/bdi.12944.
   PubMed Web of Science ®Google Scholar
• Omranifard V, Tarrahi MJ, Sharifi S, et al. Evaluation of the effect of memantine supplementation in the treatment of acute phase of mania in bipolar disorder of elderly patients: a double-blind randomized controlled trial. Adv Biomed Res. 2018;7(1):148.
   PubMedGoogle Scholar
• Hegerl U, Mergl R, Sander C, et al. A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study). Eur Neuropsychopharmacol. 2018;28(1):185–194.
   PubMed Web of Science ®Google Scholar
• Xiao L, Ganocy SJ, Findling RL, et al. Baseline characteristics and early response at week 1 predict treatment outcome in adolescents with bipolar manic or mixed episode treated with olanzapine: results from a 3-week, randomized, placebo-controlled trial. J Clin Psychiatry. 2017 Nov /Dec;78(9):e1158–e1166.
   PubMed Web of Science ®Google Scholar
• Conus P, Berk M, Cotton SM, et al. Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: an 8-week randomised controlled trial. Eur Psychiatry. 2015 Nov;30(8):975–982.
   PubMed Web of Science ®Google Scholar
• Fallah E, Arman S, Najafi M, et al. Effect of tamoxifen and lithium on treatment of acute mania symptoms in children and adolescents. Iran J Child Neurol. 2016 Spring;;10(2):16–25.
   PubMed Web of Science ®Google Scholar
• Weiser M, Levi L, Levine SZ, et al. A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bipolar Disord. 2017 Jun;19(4):285–294.
   PubMed Web of Science ®Google Scholar
• Köhler-Forsberg O, Sylvia LG, Fung V, et al. Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: findings from the Bipolar CHOICE and LiTMUS trials. Depress Anxiety. 2020 Jun 29. doi: 10.1002/da.23069
   Web of Science ®Google Scholar
• El-Mallakh RS, Vöhringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial. J Affect Disord. 2015 Sep;15(184):318–321.
   Google Scholar
• Vöhringer PA, Ostacher MJ, El-Mallakh RS, et al. Antidepressants in type II versus type I bipolar depression: a randomized discontinuation trial. J Clin Psychopharmacol. 2015 Oct;35(5):605–608.
   PubMed Web of Science ®Google Scholar
• Tada M, Uchida H, Mizushima J, et al. Antidepressant dose and treatment response in bipolar depression: reanalysis of the systematic treatment enhancement program for bipolar disorder (STEP-BD) data. J Psychiatr Res. 2015 Sep;68:151–156.
   PubMed Web of Science ®Google Scholar
• Frye MA, Amchin J, Bauer M, et al. Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments. Int J Bipolar Disord. 2015 Dec;3(1):34.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Nuss S, Gao D, et al. Asenapine in the treatment of bipolar depression. Psychopharmacol Bull. 2020 Mar 12;50(1):8–18.
   PubMedGoogle Scholar
• Berk M, Tiller JW, Zhao J, et al. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry. 2015;76(6):728–734.
   PubMed Web of Science ®Google Scholar
• Finzi E, Kels L, Axelowitz J, et al. Botulinum toxin therapy of bipolar depression: a case series. J Psychiatr Res. 2018 Sep;104:55–57.
   PubMed Web of Science ®Google Scholar
• Aladeen T, Westphal E, Lee Y, et al. The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: a case series. Perspect Psychiatr Care. 2018 Oct;54(4):507–513.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Vieta E, Earley W. Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial. Int Clin Psychopharmacol. 2020 May;35(3):147–156.
   PubMed Web of Science ®Google Scholar
• Earley WR, Burgess M, Rekeda L, et al. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. J Affect Disord. 2020 Feb;15(263):386–395.
   Google Scholar
• Earley WR, Burgess MV, Khan B, et al. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord. 2020 Jun;22(4):372–384.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Suppes T, Earley W, et al. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. CNS Spectr. 2020 Aug;25(4):502–510.
   PubMed Web of Science ®Google Scholar
• Earley W, Burgess MV, Rekeda L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry. 2019 Jun 1;176(6):439–448.
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016 Mar 1;173(3):271–281.
   PubMed Web of Science ®Google Scholar
• Halaris A, Cantos A, Johnson K, et al. Modulation of the inflammatory response benefits treatment-resistant bipolar depression: a randomized clinical trial. J Affect Disord. 2020 Jan;15(261):145–152.
   Google Scholar
• Murata S, Murphy M, Hoppensteadt D, et al. Effects of adjunctive inflammatory modulation on IL-1β in treatment resistant bipolar depression. Brain Behav Immun. 2020 Jul;87:369–376.
   PubMed Web of Science ®Google Scholar
• Edberg D, Hoppensteadt D, Walborn A, et al. Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment. J Psychiatr Res. 2018 Jun l;102:1–7.
   PubMed Web of Science ®Google Scholar
• Mehrpooya M, Yasrebifar F, Haghighi M, et al. Evaluating the effect of coenzyme Q10 augmentation on treatment of bipolar depression: a double-blind controlled clinical trial. J Clin Psychopharmacol. 2018 Oct;38(5):460–466.
   PubMed Web of Science ®Google Scholar
• Toniolo RA, Silva M, Fernandes FBF, et al. A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression. J Neural Transm (Vienna). 2018 Feb;125(2):247–257.
   PubMed Web of Science ®Google Scholar
• Lee Y, Mansur RB, Brietzke E, et al. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Brain Behav Immun. 2020 Aug;88:631–639.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Subramaniapillai M, Lee Y, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiatry. 2019 May 8;76(8):783–790.
   PubMed Web of Science ®Google Scholar
• Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, et al. Can ‘floating’ predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression. J Psychiatr Res. 2020 Jul;30(130):280–285.
   Google Scholar
• Chen MH, Cheng CM, Gueorguieva R, et al. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study. Neuropsychopharmacology. 2019 Nov;44(12):2112–2118.
   PubMed Web of Science ®Google Scholar
• Park M, Newman LE, Gold PW, et al. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. J Psychiatr Res. 2017 Jan;84:113–118.
   PubMed Web of Science ®Google Scholar
• Grunebaum MF, Ellis SP, Keilp JG, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disord. 2017 May;19(3):176–183.
   PubMed Web of Science ®Google Scholar
• Vande Voort JL, Ballard ED, Luckenbaugh DA, et al. Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder. J Clin Psychiatry. 2017 Sep /Oct;78(8):1068–1074.
   PubMed Web of Science ®Google Scholar
• Saligan LN, Luckenbaugh DA, Slonena EE, et al. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. J Affect Disord. 2016;194:115–119.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015 Dec;45(16):3571–3580.
   PubMed Web of Science ®Google Scholar
• Xu AJ, Niciu MJ, Lundin NB, et al. Lithium and valproate levels do not correlate with ketamine’s antidepressant efficacy in treatment-resistant bipolar depression. Neural Plast. 2015;2015:858251.
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2015 Jun;17(4):438–443.
   PubMed Web of Science ®Google Scholar
• Shi S, Li L, Song L, et al. Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder. Pak J Pharm Sci. 2018 Nov 31;31(6(Special)):2775–2778.
   PubMed Web of Science ®Google Scholar
• Nzeyimana A, Saunders KE, Geddes JR, et al. Lamotrigine therapy for bipolar depression: analysis of self-reported patient data. JMIR Ment Health. 2018;5(4):e63.
   PubMed Web of Science ®Google Scholar
• Simon J, Geddes JR, Gardiner A, et al. Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL). Bipolar Disord. 2018 Dec;;20(8):733–745.
   PubMed Web of Science ®Google Scholar
• Wesseloo R, Liu X, Clark CT, et al. Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: a population-based cohort study. J Affect Disord. 2017 Aug;15(218):394–397.
   Google Scholar
• Geddes JR, Gardiner A, Rendell J, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial. Lancet Psychiatry. 2016 Jan;3(1):31–39.
   PubMed Web of Science ®Google Scholar
• Bauer M, Berman S, Stamm T, et al. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. Mol Psychiatry. 2016 Feb;21(2):229–236.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Martens BE, Mori N, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2015 Jan;30(1):6–13.
   PubMed Web of Science ®Google Scholar
• Caldieraro MA, Dufour S, Sylvia LG, et al. Treatment outcomes of acute bipolar depressive episode with psychosis. Depress Anxiety. 2018 May;35(5):402–410.
   PubMed Web of Science ®Google Scholar
• Raison CL, Pikalov A, Siu C, et al. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain Behav Immun. 2018 Oct;73:717–724.
   PubMed Web of Science ®Google Scholar
• DelBello MP, Goldman R, Phillips D, et al. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2017 Dec;56(12):1015–1025.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Bacci ED, Ng-Mak D, et al. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016 May;23(16):157.
   Google Scholar
• Suppes T, Kroger H, Pikalov A, et al. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res. 2016 Jul;78:86–93.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Bacci ED, Wyrwich KW, et al. The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial. Int J Bipolar Disord. 2016 Dec;4(1):7.
   PubMedGoogle Scholar
• Chapel S, Chiu YY, Hsu J, et al. Lurasidone dose response in bipolar depression: a population dose-response analysis. Clin Ther. 2016 Jan 1;38(1):4–15.
   PubMed Web of Science ®Google Scholar
• Calabrese J, Rajagopalan K, Ng-Mak D, et al. Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression. Int Clin Psychopharmacol. 2016 May;31(3):147–154.
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Forester BP, Tsai J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. J Clin Psychiatry. 2016 Oct;77(10):e1324–e1331.
   PubMed Web of Science ®Google Scholar
• Loebel A, Siu C, Rajagopalan K, et al. Recovery in bipolar depression: post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. J Affect Disord. 2015 Nov 1;186:376–382.
   PubMed Web of Science ®Google Scholar
• Husain MI, Chaudhry IB, Khoso AB, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry. 2020 Jun;7(6):515–527.
   PubMed Web of Science ®Google Scholar
• Savitz JB, Teague TK, Misaki M, et al. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry. 2018 Jan 24;8(1):27.
   PubMedGoogle Scholar
• Ellegaard PK, Licht RW, Nielsen RE, et al. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study. J Affect Disord. 2019 Feb;15(245):1043–1051.
   Google Scholar
• Berk M, Turner A, Malhi GS, et al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med. 2019 Jan 25;17(1):18.
   PubMed Web of Science ®Google Scholar
• Bauer IE, Green C, Colpo GD, et al. A double-blind, randomized, placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression. J Clin Psychiatry. 2018 Dec 4;80(1):18m12200.
   PubMed Web of Science ®Google Scholar
• Panizzutti B, Bortolasci C, Hasebe K, et al. Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression. Acta Neuropsychiatr. 2018 Dec;30(6):334–341.
   PubMed Web of Science ®Google Scholar
• Walker DJ, DelBello MP, Landry J, et al. Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination. Child Adolesc Psychiatry Ment Health. 2017;11(1):34.
   PubMedGoogle Scholar
• Wang G, Cheng Y, Wang JN, et al. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study. Neuropsychiatr Dis Treat. 2016;12:2077–2087.
   PubMed Web of Science ®Google Scholar
• Detke HC, DelBello MP, Landry J, et al. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):217–224.
   PubMed Web of Science ®Google Scholar
• Aftab A, Kemp DE, Ganocy SJ, et al. Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. J Affect Disord. 2019 Feb;15(245):957–964.
   Google Scholar
• Daftary S, Yon JM, Choi EK, et al. Microtubule associated protein 2 in bipolar depression: impact of pregnenolone. J Affect Disord. 2017 Aug 15;218:49–52.
   PubMed Web of Science ®Google Scholar
• Chang K, DelBello M, Garrett A, et al. Neurofunctional correlates of response to quetiapine in adolescents with bipolar depression. J Child Adolesc Psychopharmacol. 2018 Jul /Aug;28(6):379–386.
   PubMed Web of Science ®Google Scholar
• Murasaki M, Koyama T, Kanba S, et al. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression. Psychopharmacology (Berl). 2018 Oct;235(10):2859–2869.
   PubMed Web of Science ®Google Scholar
• Li H, Gu N, Zhang H, et al. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2016 Apr;233(7):1289–1297.
   PubMed Web of Science ®Google Scholar
• Marsh WK, Penny JL, Rothschild AJ. Vitamin D supplementation in bipolar depression: a double blind placebo controlled trial. J Psychiatr Res. 2017 Dec;95:48–53.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Jin N, Johnson B, et al. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. Int J Bipolar Disord. 2018 Jun 10;6(1):14.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. J Affect Disord. 2018 Feb;227:649–656.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a double-blind, placebo-controlled, randomized withdrawal study. J Affect Disord. 2018 Dec;1(241):425–432.
   Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry. 2017 Mar;78(3):324–331.
   PubMed Web of Science ®Google Scholar
• Ketter TA, Amchin J, Frye MA, et al. Long-term safety and efficacy of armodafinil in bipolar depression: a 6-month open-label extension study. J Affect Disord. 2016 Jun;197:51–57.
   PubMed Web of Science ®Google Scholar
• Szegedi A, Durgam S, Mackle M, et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry. 2018 Jan 1;175(1):71–79.
   PubMed Web of Science ®Google Scholar
• Pisanu C, Congiu D, Manchia M, et al. Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment. Pharmacogenomics. 2020 Jun;21(8):533–540.
   PubMed Web of Science ®Google Scholar
• Kang MG, Qian H, Keramatian K, et al. Lithium vs valproate in the maintenance treatment of bipolar I disorder: a post-hoc analysis of a randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry. 2020 Mar;54(3):298–307.
   PubMed Web of Science ®Google Scholar
• Morlet E, Costemale-Lacoste JF, Poulet E, et al. Psychiatric and physical outcomes of long-term use of lithium in older adults with bipolar disorder and major depressive disorder: a cross-sectional multicenter study. J Affect Disord. 2019 Dec;1(259):210–217.
   Google Scholar
• Findling RL, McNamara NK, Pavuluri M, et al. Lithium for the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled discontinuation study. J Am Acad Child Adolesc Psychiatry. 2019 Feb;58(2):287–296.e4.
   PubMed Web of Science ®Google Scholar
• Missio G, Moreno DH, Demetrio FN, et al. A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study. Trials. 2019 Oct 26;20(1):608.
   PubMedGoogle Scholar
• Nierenberg AA, McElroy SL, Friedman ES, et al. Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry. 2016 Jan;77(1):90–99.
   PubMed Web of Science ®Google Scholar
• Daglas R, Cotton SM, Allott K, et al. A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: a 12-month follow-up study. Eur Psychiatry. 2016 Jan;31:20–28.
   PubMed Web of Science ®Google Scholar
• Hayes JF, Marston L, Walters K, et al. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry. 2016 Feb;15(1):53–58.
   PubMed Web of Science ®Google Scholar
• Adida M, Jollant F, Clark L, et al. Lithium might be associated with better decision-making performance in euthymic bipolar patients. Eur Neuropsychopharmacol. 2015 Jun;25(6):788–797.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Pikalov A, Streicher C, et al. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol. 2017 Sep;27(9):865–876.
   PubMed Web of Science ®Google Scholar
• Eslami Shahrbabaki M, Sabouri S, Sabahi A, et al. The efficacy of probiotics for treatment of bipolar disorder-type 1: a randomized, double-blind, placebo controlled trial. Iran J Psychiatry. 2020 Jan;15(1):10–16.
   PubMedGoogle Scholar
• Kanba S, Murasaki M, Koyama T, et al. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression. BMC Psychiatry. 2019 Jun 26;19(1):198.
   PubMedGoogle Scholar
• Mahableshwarkar AR, Calabrese JR, Macek TA, et al. Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial. J Affect Disord. 2017 Oct 15;221:275–282.
   PubMed Web of Science ®Google Scholar
• Valdes M, Bertolin S, Qian H, et al. Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: a post hoc analysis. J Affect Disord. 2019 Mar 1;246:861–866.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Beaulieu S, Schaffer A, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial. Mol Psychiatry. 2016 Aug;21(8):1050–1056.
   PubMed Web of Science ®Google Scholar
• Kauer-Sant’Anna M, Frey BN, Fijtman A, et al. Adjunctive tianeptine treatment for bipolar disorder: a 24-week randomized, placebo-controlled, maintenance trial. J Psychopharmacol. 2019 Apr;33(4):502–510.
   PubMed Web of Science ®Google Scholar
• Strejilevich SA, Martino DJ, Marengo E, et al. Long-term worsening of bipolar disorder related with frequency of antidepressant exposure. Ann Clin Psychiatry. 2011 Aug;23(3):186–192.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Ghaemi SN, Sagduyu K, et al. Antidepressant-associated Chronic irritable dysphoria (ACID) in STEP-BD Patients. J Affect Disord. 2008 Dec;111(2–3):372–377.
   PubMed Web of Science ®Google Scholar
• Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007 Apr 26;356(17):1711–1722.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Perlis RH, Thase ME, et al. Aims and results of the nimh systematic treatment enhancement program for bipolar disorder (STEP-BD). CNS Neurosci Ther. 2012 Mar;18(3):243–249.
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Whitham EA, Vohringer PA. et al. Citalopram for acute and preventive efficacy in bipolar depression (CAPE-BD): a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. Med Hypotheses. 2021 Jan 12; 82(1):19m13136. 22. doi: 10.4088/JCP.19m13136.
   Google Scholar
• McIntyre RS, Calabrese JR. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin. 2019 Nov;35(11):1993–2005.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Stubbs B, De Berardis D, et al. Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials. Int J Mol Sci. 2016 Feb 16;17(2):241.
   PubMed Web of Science ®Google Scholar
• Lindström L, Lindström E, Nilsson M, et al. Maintenance therapy with second generation antipsychotics for bipolar disorder – a systematic review and meta-analysis. J Affect Disord. 2017 Apr;15(213):138–150.
   Google Scholar
• Bessonova L, Velligan DI, Weiden PJ, et al. Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey. BMC Psychiatry. 2020 Jul 6;20(1):354.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini DA, Basile VS, et al. Antipsychotic-induced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol. 2003 Aug;23(4):323–327.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006 Apr;51(5):274–280.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cha DS, Kim RD, et al. A review of FDA-approved treatment options in bipolar depression. CNS Spectr. 2013 Dec;18(Suppl 1):4–20.
   PubMedGoogle Scholar
• Barton BB, Segger F, Fischer K, et al. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020 Mar;19(3):295–314.
   PubMed Web of Science ®Google Scholar
• Gill H, Kang S, Lee Y, et al. The long-term effect of bariatric surgery on depression and anxiety. J Affect Disord. 2019 Mar;1(246):886–894.
   Google Scholar
• Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016 Jun;30(6):495–553.
   PubMed Web of Science ®Google Scholar
• Bobo WV. The diagnosis and management of bipolar I and II disorders: clinical practice update. Mayo Clin Proc. 2017 Oct;92(10):1532–1551.
   PubMed Web of Science ®Google Scholar
• Hibar DP, Westlye LT, Doan NT, et al. Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA bipolar disorder working group. Mol Psychiatry. 2018 Apr;23(4):932–942.
   PubMed Web of Science ®Google Scholar
• Wlodarczyk BJ, Ogle K, Lin LY, et al. Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disord. 2015 Sep;17(6):615–625.
   PubMed Web of Science ®Google Scholar
• Bersudsky Y, Applebaum J, Gaiduk Y, et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord. 2010 Jun;12(4):376–382.
   PubMed Web of Science ®Google Scholar
• Shaltiel G, Mark S, Kofman O, et al. Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep. 2007 Jul-Aug;59(4):402–407.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Huff MO. Mood stabilizers and ion regulation. Harv Rev Psychiatry. 2001 Jan-Feb;9(1):23–32.
   PubMed Web of Science ®Google Scholar
• Brown ME, El-Mallakh RS. Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures. Ther Clin Risk Manag. 2010 Apr;15(6):103–109.
   Google Scholar
• Amon JS, Johnson SB, El-Mallakh RS. Asenapine for the Control of Physical Aggression: a Prospective Naturalist Pilot Study. Psychopharmacol Bull. 2017 Jan 26;47(1):27–32.
   PubMedGoogle Scholar
• Nakamura T, Kubota T, Iwakaji A, et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016 Jan 14;10:327–338.
   PubMed Web of Science ®Google Scholar
• Periclou A, Willavize S, Jaworowicz D, et al. Relationship between plasma concentrations and clinical effects of cariprazine in patients with schizophrenia or bipolar mania. Clin Transl Sci. 2020;13(2):362–371.
   PubMed Web of Science ®Google Scholar
• Ferreri F, Drapier D, Baloche E, et al. The in vitro actions of loxapine on dopaminergic and serotonergic receptors. Time to consider atypical classification of this antipsychotic drug? Int J Neuropsychopharmacol. 2018 Apr 1;21(4):355–360.
   PubMed Web of Science ®Google Scholar
• Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012 Feb;14(1):31–40.
   PubMed Web of Science ®Google Scholar
• Ruch T, Nuss S, Yeruva RR, et al. Inhaled loxapine for acute agitation in a psychiatric emergency service. Ann Clin Psychiatry. 2020. in press.
   Google Scholar
• Gross N, Greos LS, Meltzer EO, et al. Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease – two randomized controlled trials. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):478–487.
   PubMed Web of Science ®Google Scholar
• Spyker DA, Cassella JV, Stoltz RR, et al. Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo-controlled drug-drug interaction study. Pharmacol Res Perspect. 2015 Dec;3(6):e00194.
   PubMed Web of Science ®Google Scholar
• Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers. Br J Psychiatry. 2001 Jun;178(Suppl 41):S107–S119.
   PubMedGoogle Scholar
• Gao Y, Payne RS, Schurr A, et al. Memantine reduces mania-like symptoms in animal models. Psychiatry Res. 2011 Aug 15;188(3):366–371.
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Hsu HA, Papadakis K, et al. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol. 2009 Jul-Aug;32(4):199–204.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, McIntyre RS. Bipolar disorder and inflammation. Psychiatr Clin North Am. 2016 Mar;39(1):125–137.
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002 Jun;59(6):530–537.
   PubMed Web of Science ®Google Scholar
• Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003 Jun;64(6):680–690.
   PubMed Web of Science ®Google Scholar
• Valentí M, Pacchiarotti I, Bonnín CM, et al. Risk factors for antidepressant-related switch to mania. J Clin Psychiatry. 2012 Feb;73(2):e271–e276.
   PubMedGoogle Scholar
• Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a systematic treatment enhancement program for bipolar disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010;71(4):372–380.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Anastasia A, Novello S, et al. Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2018 May;20(3):195–227.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Vázquez GH, Tondo L. Bipolar depression: a major unsolved challenge. Int J Bipolar Disord. 2020 Jan;8(1):1.
   PubMed Web of Science ®Google Scholar
• Frye MA, Prieto ML, Bobo WV, et al. Current landscape, unmet needs, and future directions for treatment of bipolar depression. J Affect Disord. 2014 Dec;169(Suppl 1):S17–S23.
   PubMedGoogle Scholar
• Bahji A, Ermacora D, Stephenson C, et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disord. 2020 May;15(269):154–184.
   Google Scholar
• Behrendt-Møller I, Madsen T, Sørensen HJ, et al. Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. Bipolar Disord. 2019 Jun;21(4):350–360.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013 Jun;27(346):f3646.
   Google Scholar
• Eyre-Watt B, Mahendran E, Suetani S, et al. The association between lithium in drinking water and neuropsychiatric outcomes: a systematic review and meta-analysis from across 2678 regions containing 113 million. Aust N Z J Psychiatry. 2020;13:4867420963740.
   Google Scholar
• Memon A, Rogers I, Fitzsimmons SMDD, et al. Association between naturally occurring lithium in drinking water and suicide rates: systematic review and meta-analysis of ecological studies. Br J Psychiatry. 2020;27:1–12.
   Google Scholar
• Tunbridge EM, Attenburrow MJ, Gardiner A, et al. Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: analysis of the CEQUEL clinical trial. Bipolar Disord. 2017 Sep;19(6):477–486.
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–538.
   PubMed Web of Science ®Google Scholar
• Kiss B, Némethy Z, Fazekas K, et al. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine. Drug Des Devel Ther. 2019 Sep;16(13):3229–3248.
   Google Scholar
• Roberts RJ, Lohano KK, El-Mallakh RS. Antipsychotics as antidepressants. Asia Pac Psychiatry. 2016 Sep;8(3):179–188.
   PubMed Web of Science ®Google Scholar
• Kato T, Ishigooka J, Miyajima M, et al. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry Clin Neurosci. 2020 Aug 22;74(12):635–644.
   Web of Science ®Google Scholar
• Ali Z, Tegin C, El-Mallakh RS. Evaluating lurasidone as a treatment option for bipolar disorder. Expert Opin Pharmacother. 2020 Feb;21(3):253–260.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Karippot A. Chronic depression in bipolar disorder. Am J Psychiatry. 2006 Aug;163(8):1337–1341.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Carvalho AF, Fusco A, et al. The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. J Affect Disord. 2020 Nov;1(276):970–983.
   Google Scholar
• Tee MMK, Au CH. A systematic review and meta-analysis of randomized sham-controlled trials of repetitive transcranial magnetic stimulation for bipolar disorder. Psychiatr Q. 2020 Dec;91(4):1225–1247.
   PubMed Web of Science ®Google Scholar
• Kishi T, Matsuda Y, Sakuma K, et al. Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis. Psychol Med. 2020 Oct 13:1–9. doi10.1017/S0033291720003505.
   PubMedGoogle Scholar
• Takeshima M. Treating mixed mania/hypomania: a review and synthesis of the evidence. CNS Spectr. 2017 Apr;22(2):177–185.
   PubMed Web of Science ®Google Scholar
• Antosik-Wójcińska AZ, Stefanowski B, Święcicki Ł. Efficacy and safety of antidepressant’s use in the treatment of depressive episodes in bipolar disorder – review of research. Psychiatr Pol. 2015;49(6):1223–1239.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 5th ed ed. Washington, DC, USA: American Psychiatric Association; 2013.
   Google Scholar
• Goldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009;166(2):173–181.
   PubMed Web of Science ®Google Scholar
• Canady VA. FDA approves esketamine treatment for MDD, suicidal ideation. 2020;30(31):6–7. Ment Health Wkly.
   Google Scholar
• Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013 May 11;381(9878):1672–1682.
   PubMed Web of Science ®Google Scholar
• Kishi T, Sakuma K, Okuya M, et al. Recurrence of mania or depression among adult bipolar patients who continued using lithium: a single-group summary meta-analysis of randomized trials. J Clin Psychopharmacol. 2020 Sep /Oct;40(5):468–474.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Maritan E, Ferranti R, et al. Lithium exposure during pregnancy and the postpartum period: a systematic review and meta-analysis of safety and efficacy outcomes. Am J Psychiatry. 2020 Jan 1;177(1):76–92.
   PubMed Web of Science ®Google Scholar
• El-Mallakh PL, El-Mallakh RS. Adherence and assured administration of medications in bipolar patients. Curr Drug Deliv. 2013 Dec;10(6):706–712.
   PubMed Web of Science ®Google Scholar
• Ott CV, Vinberg M, Kessing LV, et al. The effect of erythropoietin on cognition in affective disorders – Associations with baseline deficits and change in subjective cognitive complaints. Eur Neuropsychopharmacol. 2016 Aug;26(8):1264–1273.
   PubMed Web of Science ®Google Scholar
• Miskowiak KW, Vinberg M, Macoveanu J, et al. Effects of erythropoietin on hippocampal volume and memory in mood disorders. Biol Psychiatry. 2015 Aug 15;78(4):270–277.
   PubMed Web of Science ®Google Scholar
• Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018 Jun;15(389):21–27.
   Google Scholar
• Solmi M, Pigato G, Kane JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018 May 14;12:1215–1238.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Calabrese JR, Nierenberg AA, et al. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. J Affect Disord. 2019 Mar;1(246):217–223.
   Google Scholar
• Josiassen RC, Kane JM, Liang GS, et al. Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder. Psychopharmacol Bull. 2017 Aug 1;47(3):61–68.
   PubMedGoogle Scholar
• Rado J. von Ammon Cavanaugh S. A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. J Clin Psychopharmacol. 2016 Apr;36(2):163–168.
   PubMed Web of Science ®Google Scholar
• Talaeı A, Farıdhosseını F, Kazemı H, et al. Topiramatın şizofreni ve iki uçlu duygudurum i bozukluğu olan hastalarda ilaca bağli kilo alimina etkileri: doz ayarlarinin seçkisiz klinik çalişması [Effect of topiramate on drug associated weight gain of patients with schizophrenia and bipolar i disorders: a dose ranging randomized trial]. Turk Psikiyatri Derg. 2016 Summer;27(2):0. Turkish with English translation.
   PubMedGoogle Scholar
• Chaudhary AMD, M F K, S S D, et al. A review of samidorphan: a novel opioid antagonist. Cureus. 2019;11(7):e5139.
   PubMed Web of Science ®Google Scholar
• Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177(12):1168-1178.
   Web of Science ®Google Scholar
• Sun L, Yagoda S, Yao B, et al. Combination of olanzapine and samidorphan has no clinically significant effect on the pharmacokinetics of lithium or valproate. Clin Drug Investig. 2020 Jan;40(1):55–64.
   PubMed Web of Science ®Google Scholar
• Kessing LV, Bauer M, Nolen WA, et al. Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord. 2018;20(5):419–431.
   Web of Science ®Google Scholar
• El-Mallakh RS. Adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007 Aug 9;357(6):615–616. 615; author reply
   PubMedGoogle Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003 Nov;60(11):1079–1088. Erratum in: Arch Gen Psychiatry. 2004 Feb;61(2):176
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J, Brunswick DJ, et al. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression – low manic switch rate. Bipolar Disord. 2004 Feb;6(1):75–81.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol. 2005 Sep;20(5):257–264.
   PubMed Web of Science ®Google Scholar
• Saha S, Lim CCW, Cannon DL, et al. Co-morbidity between mood and anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2020 Nov;22. doi: 10.1002/da.23113
   Web of Science ®Google Scholar
• Bandelow B. Current and novel psychopharmacological drugs for anxiety disorders. Adv Exp Med Biol. 2020;1191:347–365.
   PubMed Web of Science ®Google Scholar
• Fava GA. May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Ther Adv Psychopharmacol. 2020 Nov;2(10):2045125320970325.
   Google Scholar
• El-Mallakh RS, Roberts RJ, Swann A, et al. Tardive dysphoria: antidepressant-induced chronic depression. Ir J Psychol Med. 2011 Mar;28(1):38–41.
   PubMedGoogle Scholar
• Togay B, El-Mallakh RS. Posttraumatic stress disorder: from pathophysiology to pharmacology. Curr Psychiatry. 2020;19(5):33–39.
   Google Scholar
• Nahas Z, Kozel FA, Li X, et al. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disord. 2003 Feb;5(1):40–47.
   PubMed Web of Science ®Google Scholar
• Myczkowski ML, Fernandes A, Moreno M, et al. Cognitive outcomes of TMS treatment in bipolar depression: safety data from a randomized controlled trial. J Affect Disord. 2018;235:20–26.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012 Jun 1;71(11):939–946.
   PubMed Web of Science ®Google Scholar
• Delfino RS, Del-Porto JA, Surjan J, et al. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression. J Affect Disord. 2021;278:515–518.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Ali Z. Extra-synaptic modulation of GABAA and efficacy in bipolar disorder. Med Hypotheses. 2021;147:110501.
   Web of Science ®Google Scholar